Exentis delivers latest pharma production system to Italy

28 March 2024 11:02

Supporting partner

Stetten - Exentis has delivered its latest pharma production system to an Italian company. The technology platform for the production of 3D-printed tablets, which according to Exentis is globally unique, can manufacture up to 200 million units per year, with up to three active ingredients per tablet.

The Exentis Group has delivered the latest generation of its pharma production system to a contract development and manufacturing organization in Italy. This system for the production of 3D-printed tablets features a capacity of up to 10 million units per year, according to a press release. Moreover, there is the potential for a modular expansion of the platform, which would at present increase the production capacity to up to 200 million tablets per year. In this way, the company is “a global pioneer in technology platforms for the production of 3D-printed pharmaceutical products”, according to Gereon Heinemann, CEO of Exentis.

According to the information, the Exentis 3D technology platform makes it possible to additively manufacture tablets with a freely adjustable release profile of active pharmaceutical ingredients in the human or animal body for the first time. In cases where it may be necessary to administer or take the same medication several times a day or during the night, this can be achieved via a single daily dose. This is also a great advantage for pets, for example.

The Exentis technology therefore “creates a completely new market segment”, as the company writes in the press release. Alongside the pharma market, in future Exentis will seek to tap into other attractive growth markets, in which products are manufactured by way of clean room technology as well. These may include sectors such as pet medicine and nutritional supplements.

According to Exentis, the industrialized additive manufacturing facilitated by the company’s 3D technology platform is universally applicable, in clean room settings as well as for industrial applications. Users have a free choice of materials, ranging from active pharmaceutical ingredients and bio-printing products all the way through to metals, ceramics and polymers. In addition, the cold printing process used for this helps to conserve materials and resources. ce/mm

Supporting partner

Swiss Pavilion Digital